Keywords: b-ms, gilead, set, up, jv, market, triple

B-MS and Gilead set up JV to market triple AIDS drugs

Article | 10 January 2005

Print This

US firms Bristol-Myers Squibb and Gilead Sciences have announced details of a joint venture to develop and commercialize the fixed-dose ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in